Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03678012 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of Anti-biofilm Effects of Ferumoxytol (Feraheme) Using an in Situ Biofilm Demineralization Model
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT03678012: Completed Early Phase 1 study, sponsored by University of Pennsylvania.
NCT03678012 is a Early Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03678012, a Early Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
To evaluate the effects of a clinically approved and commercially available iron oxide formulation Ferumoxytol (Feraheme®) to control cariogenic biofilms and enamel demineralization. This study will be testing topical application of Ferumoxytol extra-orally using a standard in situ biofilm demineralization model.
Interventions
- DRUG Hydrogen Peroxide
- DRUG Water
- DRUG Ferumoxytol/Hydrogen peroxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-06-07 |
| Est. Completion | 2018-08-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03678012
The ClinicalTrials.gov registry entry for NCT03678012 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Hydrogen Peroxide is the first listed.
NCT03678012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03678012 about?
NCT03678012 is a clinical study titled "Evaluation of Anti-biofilm Effects of Ferumoxytol (Feraheme) Using an in Situ Biofilm Demineralization Model". To evaluate the effects of a clinically approved and commercially available iron oxide formulation Ferumoxytol (Feraheme®) to control cariogenic biofilms and enamel demineralization. This study will be testing topical application of Ferumoxytol extra-orally using a standard in situ biofilm demineral...
What is the current status of trial NCT03678012?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2018-06-07. Estimated completion is 2018-08-16.
What interventions are being tested in trial NCT03678012?
The interventions under investigation include: Hydrogen Peroxide (DRUG), Water (DRUG), Ferumoxytol/Hydrogen peroxide (DRUG).
Who is sponsoring clinical trial NCT03678012?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.